Yui Harada

Title: Yui Harada: Innovator in NK Cell Therapies

Introduction

Yui Harada is a prominent inventor based in Saitama, Japan, known for her significant contributions to the field of immunology. She has been awarded a total of six patents, focusing on the development of highly active natural killer (NK) cells and their therapeutic applications.

Latest Patents

One of her latest patents is titled "Highly active NK cell and use thereof." This invention provides an NK cell exhibiting higher cytotoxic activity, aimed at creating a pharmaceutical composition for NK cell therapies that are expected to be highly effective. The NK cell described in this patent possesses specific characteristics, including being CD16-positive, highly expressing CD56, and being CD57-negative. Additionally, it is NKG2C-positive, NKG2A-negative or lowly expressing NKG2A, and CD94-positive. Another notable patent is "Population of CD3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same." This invention relates to an immunocyte with enhanced cytotoxic activity and provides a cell population that includes CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells, which can infiltrate solid tumors.

Career Highlights

Yui Harada has worked with Gaia Biomedicine Inc., where she has contributed to advancing NK cell therapies. Her innovative work has positioned her as a key figure in the field of immunotherapy.

Collaborations

Throughout her career, Yui has collaborated with notable individuals such as Yoshikazu Yonemitsu and Koji Teraishi, enhancing her research and development efforts in the field.

Conclusion

Yui Harada's contributions to NK cell therapies and her innovative patents highlight her role as a leading inventor in the field of immunology. Her work continues to pave the way for advancements in cancer treatment and immunotherapy.